Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Hormone-Sensitive Prostate Cancer × PROSTVAC × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Stage I Prostate Adenocarcinoma AJCC v7 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Metastatic Hormone-Sensitive Prostate Cancer 1

Interventions

PROSTVAC 1 Nivolumab 1 Leukapheresis 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡